PXT 3003 is a drug candidate developed by Pharnext. It has already been the subject of two clinical trials, launched in 2010 and 2015, and of an international phase 3 trial between 2021 and 2023, notably in France. Its preliminary results were announced in a press release in December 2023.
- The ONLS score was reported to have improved in both patients treated with PXT 3003 and those treated with placebo.
- The treatment is well tolerated.
For the time being, these are only preliminary results, and Pharnext says it is continuing to analyse them in greater depth.